# Phase II Study With the Trifunctional Antibody Ertumaxomab to Treat Metastatic Breast Cancer After Progression on Trastuzumab Therapy

> **NCT00522457** · PHASE2 · TERMINATED · sponsor: **Neovii Biotech** · enrollment: 19 (actual)

## Conditions studied

- Metastatic Breast Cancer
- Advanced Breast Cancer

## Interventions

- **DRUG:** ertumaxomab

## Key facts

- **NCT ID:** NCT00522457
- **Lead sponsor:** Neovii Biotech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-01
- **Primary completion:** 2009-12
- **Final completion:** 2009-12
- **Target enrollment:** 19 (ACTUAL)
- **Why stopped:** change in development plan, not due to safety concerns.
- **Last updated:** 2011-04-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00522457

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00522457, "Phase II Study With the Trifunctional Antibody Ertumaxomab to Treat Metastatic Breast Cancer After Progression on Trastuzumab Therapy". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00522457. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*